Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)-Reference-Cited by-同舟云学术

Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)

Published:2012-11-01 Issue:1 Volume:12 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Sicras-Mainar Antoni,Ibáñez-Nolla Jordi,Cifuentes Isabel,Guijarro Pablo,Navarro-Artieda Ruth,Aguilar Lorenzo

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/article/10.1186/1471-2334-12-283/fulltext.html

Reference52 articles.

1. British Thoracic Society: Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009, 64 (Suppl. III): iii1-iii55.

2. Almirall J, Bolíbar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolomé M, Balanzó X: Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000, 15: 757-763. 10.1034/j.1399-3003.2000.15d21.x.

3. Brown SM, Dean NC: Defining and predicting severe community-acquired pneumonia. Curr Opin Infect Dis. 2010, 23: 158-164. 10.1097/QCO.0b013e3283368333.

4. de Miguel DJ, Alvarez-Sala JL: Prognostic factors in community-acquired pneumonia [Article in Spanish]. An Med Interna. 2007, 24: 465-466.

5. Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, Hernández I, De Ory F, Royo G, Hidalgo AM: Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect. 2005, 11: 788-800. 10.1111/j.1469-0691.2005.01226.x.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings;Vaccine;2024-04

2. Factors affecting hospital discharge outcomes in patients with community-acquired pneumonia: A retrospective epidemiological study (2014-2021);The American Journal of the Medical Sciences;2023-08

3. Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors;Human Vaccines & Immunotherapeutics;2023-01-02

4. All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain;Expert Review of Pharmacoeconomics & Outcomes Research;2022-01-17

5. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY);Open Forum Infectious Diseases;2021-12-18